Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration

Gregory E. Bean, Victoria Scott, Lisa Yee, Brooke Ratliff-Daniel, Michelle M. Troch, Pearl H Seo, Michelle L. Bowie, Paul K. Marcom, Jaimie Slade, Bruce F. Kimler, Carol J. Fabian, Carola M. Zalles, Gloria Broadwater, Joseph C. Baker, Lee G. Wilke, Victoria L. Seewaldt

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Methylation of the retinoic acid receptor-β2 (RARβ2) P2 promoter is hypothesized to be an important mechanism for loss of RARβ2 function during early mammary carcinogenesis. The frequency of RARβ2 P2 methylation was tested in (a) 16 early stage breast cancers and (b) 67 random periareolar fine needle aspiration (RPFNA) samples obtained from 38 asymptomatic women who were at increased risk for breast cancer. Risk was defined as either (a) 5-year Gail risk calculation ≥1.7%; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. RARβ2 P2 promoter methylation was assessed at two regions, M3 (-51 to 162 bp) and M4 (104-251 bp). In early stage cancers, M4 methylation was observed in 11 of 16 (69%) cases; in RPFNA samples, methylation was present at M3 and M4 in 28 of 56 (50%) and 19 of 56 (38%) cases, respectively. RPFNAs were stratified for cytologic atypia using the Masood cytology index. The distribution of RARβ2 P2 promoter methylation was reported as a function of increased cytologic abnormality. Methylation at both M3 and M4 was observed in (a) 0 of 10 (0%) of RPFNAs with Masood scores of ≤10 (nonproliferative), (b) 3 of 20 (15%) with Masood scores of 11 to 12 (low-grade proliferative), (c) 3 of 10 (30%) with Masood scores of 13 (high-grade proliferative), and (d) 7 of 14 (50%) with Masood scores of 14 of 15 (atypia). Results from this study indicate that the RARβ2 P2 promoter is frequently methylated (69%) in primary breast cancers and shows a positive association with increasing cytologic abnormality in RPFNA.

Original languageEnglish
Pages (from-to)790-798
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume14
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Retinoic Acid Receptors
Fine Needle Biopsy
Methylation
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Hyperplasia
Cell Biology
Carcinogenesis
Breast
Biopsy
Mutation

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration. / Bean, Gregory E.; Scott, Victoria; Yee, Lisa; Ratliff-Daniel, Brooke; Troch, Michelle M.; Seo, Pearl H; Bowie, Michelle L.; Marcom, Paul K.; Slade, Jaimie; Kimler, Bruce F.; Fabian, Carol J.; Zalles, Carola M.; Broadwater, Gloria; Baker, Joseph C.; Wilke, Lee G.; Seewaldt, Victoria L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 14, No. 4, 01.04.2005, p. 790-798.

Research output: Contribution to journalArticle

Bean, GE, Scott, V, Yee, L, Ratliff-Daniel, B, Troch, MM, Seo, PH, Bowie, ML, Marcom, PK, Slade, J, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Baker, JC, Wilke, LG & Seewaldt, VL 2005, 'Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration', Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 790-798. https://doi.org/10.1158/1055-9965.EPI-04-0580
Bean, Gregory E. ; Scott, Victoria ; Yee, Lisa ; Ratliff-Daniel, Brooke ; Troch, Michelle M. ; Seo, Pearl H ; Bowie, Michelle L. ; Marcom, Paul K. ; Slade, Jaimie ; Kimler, Bruce F. ; Fabian, Carol J. ; Zalles, Carola M. ; Broadwater, Gloria ; Baker, Joseph C. ; Wilke, Lee G. ; Seewaldt, Victoria L. / Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration. In: Cancer Epidemiology Biomarkers and Prevention. 2005 ; Vol. 14, No. 4. pp. 790-798.
@article{52b806f77c274783bcad339a993e28e9,
title = "Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration",
abstract = "Methylation of the retinoic acid receptor-β2 (RARβ2) P2 promoter is hypothesized to be an important mechanism for loss of RARβ2 function during early mammary carcinogenesis. The frequency of RARβ2 P2 methylation was tested in (a) 16 early stage breast cancers and (b) 67 random periareolar fine needle aspiration (RPFNA) samples obtained from 38 asymptomatic women who were at increased risk for breast cancer. Risk was defined as either (a) 5-year Gail risk calculation ≥1.7{\%}; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. RARβ2 P2 promoter methylation was assessed at two regions, M3 (-51 to 162 bp) and M4 (104-251 bp). In early stage cancers, M4 methylation was observed in 11 of 16 (69{\%}) cases; in RPFNA samples, methylation was present at M3 and M4 in 28 of 56 (50{\%}) and 19 of 56 (38{\%}) cases, respectively. RPFNAs were stratified for cytologic atypia using the Masood cytology index. The distribution of RARβ2 P2 promoter methylation was reported as a function of increased cytologic abnormality. Methylation at both M3 and M4 was observed in (a) 0 of 10 (0{\%}) of RPFNAs with Masood scores of ≤10 (nonproliferative), (b) 3 of 20 (15{\%}) with Masood scores of 11 to 12 (low-grade proliferative), (c) 3 of 10 (30{\%}) with Masood scores of 13 (high-grade proliferative), and (d) 7 of 14 (50{\%}) with Masood scores of 14 of 15 (atypia). Results from this study indicate that the RARβ2 P2 promoter is frequently methylated (69{\%}) in primary breast cancers and shows a positive association with increasing cytologic abnormality in RPFNA.",
author = "Bean, {Gregory E.} and Victoria Scott and Lisa Yee and Brooke Ratliff-Daniel and Troch, {Michelle M.} and Seo, {Pearl H} and Bowie, {Michelle L.} and Marcom, {Paul K.} and Jaimie Slade and Kimler, {Bruce F.} and Fabian, {Carol J.} and Zalles, {Carola M.} and Gloria Broadwater and Baker, {Joseph C.} and Wilke, {Lee G.} and Seewaldt, {Victoria L.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1158/1055-9965.EPI-04-0580",
language = "English",
volume = "14",
pages = "790--798",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration

AU - Bean, Gregory E.

AU - Scott, Victoria

AU - Yee, Lisa

AU - Ratliff-Daniel, Brooke

AU - Troch, Michelle M.

AU - Seo, Pearl H

AU - Bowie, Michelle L.

AU - Marcom, Paul K.

AU - Slade, Jaimie

AU - Kimler, Bruce F.

AU - Fabian, Carol J.

AU - Zalles, Carola M.

AU - Broadwater, Gloria

AU - Baker, Joseph C.

AU - Wilke, Lee G.

AU - Seewaldt, Victoria L.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Methylation of the retinoic acid receptor-β2 (RARβ2) P2 promoter is hypothesized to be an important mechanism for loss of RARβ2 function during early mammary carcinogenesis. The frequency of RARβ2 P2 methylation was tested in (a) 16 early stage breast cancers and (b) 67 random periareolar fine needle aspiration (RPFNA) samples obtained from 38 asymptomatic women who were at increased risk for breast cancer. Risk was defined as either (a) 5-year Gail risk calculation ≥1.7%; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. RARβ2 P2 promoter methylation was assessed at two regions, M3 (-51 to 162 bp) and M4 (104-251 bp). In early stage cancers, M4 methylation was observed in 11 of 16 (69%) cases; in RPFNA samples, methylation was present at M3 and M4 in 28 of 56 (50%) and 19 of 56 (38%) cases, respectively. RPFNAs were stratified for cytologic atypia using the Masood cytology index. The distribution of RARβ2 P2 promoter methylation was reported as a function of increased cytologic abnormality. Methylation at both M3 and M4 was observed in (a) 0 of 10 (0%) of RPFNAs with Masood scores of ≤10 (nonproliferative), (b) 3 of 20 (15%) with Masood scores of 11 to 12 (low-grade proliferative), (c) 3 of 10 (30%) with Masood scores of 13 (high-grade proliferative), and (d) 7 of 14 (50%) with Masood scores of 14 of 15 (atypia). Results from this study indicate that the RARβ2 P2 promoter is frequently methylated (69%) in primary breast cancers and shows a positive association with increasing cytologic abnormality in RPFNA.

AB - Methylation of the retinoic acid receptor-β2 (RARβ2) P2 promoter is hypothesized to be an important mechanism for loss of RARβ2 function during early mammary carcinogenesis. The frequency of RARβ2 P2 methylation was tested in (a) 16 early stage breast cancers and (b) 67 random periareolar fine needle aspiration (RPFNA) samples obtained from 38 asymptomatic women who were at increased risk for breast cancer. Risk was defined as either (a) 5-year Gail risk calculation ≥1.7%; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. RARβ2 P2 promoter methylation was assessed at two regions, M3 (-51 to 162 bp) and M4 (104-251 bp). In early stage cancers, M4 methylation was observed in 11 of 16 (69%) cases; in RPFNA samples, methylation was present at M3 and M4 in 28 of 56 (50%) and 19 of 56 (38%) cases, respectively. RPFNAs were stratified for cytologic atypia using the Masood cytology index. The distribution of RARβ2 P2 promoter methylation was reported as a function of increased cytologic abnormality. Methylation at both M3 and M4 was observed in (a) 0 of 10 (0%) of RPFNAs with Masood scores of ≤10 (nonproliferative), (b) 3 of 20 (15%) with Masood scores of 11 to 12 (low-grade proliferative), (c) 3 of 10 (30%) with Masood scores of 13 (high-grade proliferative), and (d) 7 of 14 (50%) with Masood scores of 14 of 15 (atypia). Results from this study indicate that the RARβ2 P2 promoter is frequently methylated (69%) in primary breast cancers and shows a positive association with increasing cytologic abnormality in RPFNA.

UR - http://www.scopus.com/inward/record.url?scp=20144387394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387394&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-04-0580

DO - 10.1158/1055-9965.EPI-04-0580

M3 - Article

C2 - 15824145

AN - SCOPUS:20144387394

VL - 14

SP - 790

EP - 798

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -